Dr. Kraan has over 25 years of biopharmaceutical industry experience, he held senior Research & Development as well as CMO positions prior to joining AM-Pharma in 2020.
Before joining AM-Pharma, Dr. Kraan was at Pierre Fabre S.A., a multinational pharmaceutical company, where he was the head of Research & Development and responsible for the R&D strategy (France). Before Pierre Fabre, Dr. Kraan was head of R&D at Stallergenes Greer Ltd. (UK); Chief Medical Officer at Therachon (Switzerland), acquired by Pfizer; Senior Vice President, Head Innovative Medicines Respiratory and Inflammation at AstraZeneca (Sweden); Vice President, Head Clinical Research and Experimental Development Inflammation Hoffmann – La Roche (USA); Vice President, Immunosciences Bristol Myers-Squibb (USA) and Schering-Plough (currently part of Merck/MSD, USA). He has been involved in the launch of Belatacept for delayed graft function in renal transplant and Remicade for rheumatoid arthritis.
Dr. Kraan is a board-certified rheumatologist and holds a M.D. and Ph.D. in immunology from Leiden University.